

Uterine carcinosarcomas: 8-year single center experience of 25 cases

Kalpana S. Dave,
Anjana Chauhan,
Ronak Bhansali,
Ruchi Arora, Sushma Purohit

Department of Gynecology
Oncology, Gujarat Cancer &
Research Institute, Ahmedabad,
Gujarat, India

ABSTRACT

Objectives: The aim of this retrospective study was to evaluate the behavior and treatment outcomes of uterine carcinosarcomas in relation to their clinical and pathogenic features and to determine the optimal treatment strategy. Secondary objectives were to identify parameters predictive of survival. **Materials and Methods:** The hospital records of all 25 patients of uterine carcinosarcoma operated between 2000 and 2008 in Gujarat cancer research institute, Ahmedabad, were reviewed. Patients who presented with clinical evidence of recurrent disease or those who had incomplete medical records were excluded from our analysis. The status of these patients was updated up to November, 2010. Patients were classified according to the new 2009 FIGO staging system for endometrial carcinoma, to see what difference the assigned stage has on survival with the old treatment strategy. Survival was calculated by Kaplan-Meier method and compared by Log-Rank test. Median survival time was derived with the Brookmeyer 95% confidence interval. For comparison of qualitative data, Chi-Square test and Fisher exact χ^2 were used. **Results:** Median age of patients was 56 years (range, 36-77 years). Only 36% of patients had stage I at diagnosis and another 36% were stage III. Most of the tumors (56%) were with homologous sarcomatous components and 64% of tumors were high grade (grade 2/3) at diagnosis. Fifty-two percent patients received postoperative adjuvant treatment. Twelve patients had no postoperative treatment: two were lost to follow-up immediately after surgery, four could not receive adjuvant treatment on account of severe medical complications and age factor which could have increased morbidity, and six patients declined treatment. Four of these patients expired within one year of diagnosis, two other within 18 months, and rest were lost to follow-up. The difference in survival of 13 patients who had taken adjuvant treatment was significantly more than the group who had not taken adjuvant therapy ($P=0.025$). The overall 3-year disease-free survival of 13 patients who had taken adjuvant therapy was 40%. However, these adjuvant treatment modalities had borderline statistical significance on overall survival of patients ($P=0.075$). The only statistically significant predictor of survival in this study was stage of the disease ($P=0.035$). **Conclusions:** This highly aggressive uterine malignancy warrants comprehensive surgical staging to assess tumor dissemination followed by systematic adjuvant therapy in patients with both early and advanced disease. The value of pelvic Radiotherapy in addition to systemic treatment remains ill-defined. Stage is the significant predictor of survival for the disease. Our results indicate that in this highly aggressive malignancy, further exploration of potential outcome benefits of postoperative treatment, especially chemoradiation, is warranted in larger group of patients after comprehensive surgical staging.

Key words: Carcinosarcoma, FIGO staging, treatment outcome

Address for correspondence:
Dr. Sushma Purohit,
C/O Mr. R.K.Choudhary, Village &
Post- Rajoda, District- Dewas,
Madhya Pradesh, India.
E-mail: drsushmapurohit@gmail.
com

INTRODUCTION

Carcinosarcoma of uterus, also known as malignant

mixed mullerian tumor (MMMT) of uterus, in contrast to endometrial carcinoma is very rare but highly aggressive neoplasm that usually arises in postmenopausal age group. It represents the most frequent uterine sarcoma, 1.5% of all malignant uterine cancers.^[1] The frankly malignant variants grow rapidly and usually are accompanied by postmenopausal bleeding, pelvic pain, a palpable lower abdominal mass, or symptoms of metastatic disease. Most patients have enlarged uterus and the tumor protrudes through cervical os in half the patients.^[2] It accounts for 16.4% of deaths attributable to uterine malignancies. Equally

Access this article online

Quick Response Code:



Website:
www.ijmpo.org

DOI:
10.4103/0971-5851.92814

disconcerting is the lack of measurable improvement in patient's survival over the past four decades, despite more aggressive adjuvant therapeutic strategies.^[3,4] Most, but not all, uterine carcinosarcomas are monoclonal tumors and really metaplastic carcinomas. Metastases are usually from carcinomatous element and sarcomatous element is believed to be derived as a result of dedifferentiation of the carcinomatous component.^[2]

MMMT of uterus are associated with a less favorable outcome than uterine carcinoma with 5-year survival rates ranging between 33 and 39%.^[4] The most important prognostic factor is the stage of disease at the time of treatment. Survival is very poor when tumor extends beyond the uterus. The prognostic impact of other clinical and pathology parameters is controversial.^[5]

The primary treatment of MMT of uterus is surgery but high rates of both local and distant relapse after surgery presupposes the need for effective adjuvant therapies. Most recurrences develop within 12 months and at distant sites.^[6] There is neither clear evidence that adjuvant radiotherapy, chemotherapy, or both improve the overall survival of these patients, nor there is clear consensus regarding therapeutic strategies for different stages of disease.^[7] The aim of this retrospective study was to evaluate the behavior and treatment outcomes of uterine carcinosarcomas in relation to their clinical and pathogenic features and to determine the optimal treatment strategy. Secondary objectives included identification of parameters predictive of survival. As staging classification by International Federation of Obstetrics and Gynecology (FIGO) has changed in 2009, we applied this change on staging distribution and survival by stage, to see what difference the assigned stage has on survival with the old treatment strategy; however, no new treatment guidelines have been laid down in accordance with changed staging.

MATERIALS AND METHODS

The hospital records of all 25 patients of uterine carcinosarcoma operated during the period 2000-2008 in Gujarat Cancer Research Institute, Ahmedabad, were reviewed. Patients who presented with clinical evidence of recurrent disease or those who had incomplete medical records were excluded from our analysis. Institutional review board approval was obtained for the study performed. Data were retrieved from the patient's records, institutional tumor registry, and death certificates. The diagnosis was based on the original histology report signed out by two certified pathologists. The status of these patients was updated up to November, 2010. These data were used to update the patient's surgical-pathological stage of disease based on new FIGO staging for the endometrial carcinoma, which is also

recommended for uterine carcinosarcomas.^[8] Information regarding treatment, including surgery, chemotherapy, and/or radiation therapy, and follow up was collected. Patients were considered appropriately surgically staged if a lymphadenectomy was performed in stages I to III. Omentectomy was not considered part of staging procedure. With demonstrable intra-abdominal or distant metastasis, a biopsy of extrapelvic disease was considered sufficient for surgical staging. Patients were considered unstaged when they were operated outside institute and had improper or unavailable documents. Treatment failures detected in central pelvis, pelvic sidewall, pelvic and/or aortic lymph nodes were considered locoregional recurrences. Distant recurrences were defined as disease recurring in upper abdomen or in extra-abdominal sites after initial treatment. Disease-free survival (DFS) or time to recurrence after treatment was defined from date of completion of first treatment to first diagnosis of recurrent disease.

Statistical methods

SPSS (Statistical package for social sciences) for windows 13 program was used for statistical analyses in evaluating findings obtained in the study. In addition to the defining statistical methods (median, standard deviation, frequency), for comparison of qualitative data, Chi-Square test and Fisher exact χ^2 were used. Kaplan Meier survival analysis was used for survival analyses and Log Rank test was used for comparing survival data. Median survival time was derived with the Brookmeyer 95% confidence interval.

RESULTS

During the study period, 25 patients with primary uterine carcinosarcoma of uterus met the inclusion criteria. Clinical and therapeutic variables for this cohort of patients are described in Table 1. All patients underwent total abdominal hysterectomy, surgical staging except for two patients who were unstaged. Median age of patients was 58 years (range, 36-77 years). Only 36% of patients had stage I at diagnosis, another 36% were stage III, and 20% were in stage II and IV. Most of the tumors (56%) had homologous sarcomatous components and 72% of tumors were high grade (grade 2/3) at diagnosis. There was no patient with a history of pelvic radiotherapy in past in our series. Only five patients in study were premenopausal, all the rest had reached menopause spontaneously. Two of the premenopausal patients had surgical menopause at the time of presentation: one had undergone Wertheim's hysterectomy with bilateral pelvic lymph node dissection and the other had total abdominal hysterectomy with bilateral salpingo-oophorectomy. All the 20 postmenopausal patients had spontaneous menopause with ten of them operated outside. The presenting symptom was bleeding (majority with postmenopausal

bleeding and menorrhagia in premenopausal females) in 20 (80%) patients, pain in six (24%), abdominal mass or swelling in two, and discharge per vagina in two patients. In some patients, there was more than one symptom. One patient was found to have concomitant ovarian malignancy. Table 2 presents the details of symptoms. Mean follow-up period was 16 months (range, 3-65 months). Fifty-two percent patients had received postoperative adjuvant treatment. Twelve of 25 patients had taken no postoperative treatment: 2/12 were lost to follow-up immediately after surgery, 4/12 could not receive adjuvant treatment on account of severe medical complications and age factor which could have increased morbidity, and 6/12 patients declined treatment. Four of these 12 patients expired within one year of diagnosis, two other within 18 months, and rest were lost to follow-up. Four patients were refused adjuvant treatment: First was 60-year-old patient with poor performance status in stage IIIA G3 and died after nine months of surgery after distant and

locoregional recurrence due to multiorgan failure; second was 77-year-old female in stage IB G3 with postoperative burst abdomen as complication and died natural death six months after surgery with no sign of recurrence; third was 62-year-old patient in stage IA G1 with histological predominant adenosarcoma, had 11-month disease-free period after which developed unresectable pelvic recurrence, received palliative chemotherapy for it, and died three months after completion of chemotherapy due to cardiac complications; fourth patient was 50-year-old in stage II G2 with associated controlled diabetes mellitus, developed ischemic heart disease on fourth postoperative day, and died after six months of surgery without recurrence due to cardiac complication. Among patients in no adjuvant treatment arm, six patients could not receive postoperative treatment on account of associated medical comorbidity, residual disease, and advanced age with poor performance status. All these factors may have definitely affected the overall survival in no adjuvant treatment arm: four of these six patients expired within one year of diagnosis and two other within 18 months. Thirteen (52%) patients of 25 had received adjuvant treatment: ten patients had taken only radiotherapy, one had whole pelvic radiation (WPI) with para-aortic radiation, and two had both radiotherapy and chemotherapy. Postoperative treatment was not absolutely consistent; however, it mainly consisted of adjuvant WPI. WPI consisted of megavoltage photonic irradiation by 6 MeV linear accelerator delivering about 4 500 to 5 000 cGy to whole pelvis over 4 to 5 weeks in daily fractions of 180 to 200 cGy through AP-PA opposed fields or four-field "box" technique. This was followed by brachytherapy using two iridium-192 insertions each delivering 6.5 Gy high dose rate brachytherapy or 20 Gy low dose rate brachytherapy to the vaginal surface.

Ten patients had WPI, one had WPI with para-aortic radiation because of positive para-aortic nodes, and two patients had radiation therapy along with chemotherapy. Of the two patients who received both radiotherapy and chemotherapy, one patient had coexistent stage IIIB ovarian serous papillary adenocarcinoma and other patient had stage IVB disease with only one-sided inguinal node metastases. Patient with inguinal node metastases underwent groin dissection along with surgical staging and postoperative three cycles of cisplatin and epirubicin followed by WPI. This was the only case of advanced disease with long disease-free period of 52 months after which she was lost to follow-up.

Table 3 presents summary of postoperative treatment and recurrence. Of the 13 patients who had taken adjuvant treatment, recurrence was recorded in total five (38.5%) patients, of which four patients had only postoperative radiation as adjuvant therapy and one patient had chemotherapy followed by radiation therapy because of

Table 1: Patients' clinical characteristics

Characteristics	No.	%
Surgery	25	100
Simple hysterectomy	23	
Radical hysterectomy	1	
Subtotal hysterectomy	1	
Lymphadenectomy		
Pelvic only	15	60
Pelvic-aortic	1	4
None	9	36
Stage		
I	9 {IA 6, IB 3}	36
II	3	12
III	9 {IIIA 6, IIIB 1, IIIC1 1, IIIC2 1}	36
IV	2	8
Unstaged	2	8
Histological classification based on:		
Sarcoma components		
Homologous	14	56
Heterologous	11	44
Grade of tumor		
Grade I	7	28
Grade II	5	20
Grade III	13	52

Table 2: Presenting symptoms

Symptoms	No.	%
Postmenopausal bleeding	15	80
Menorrhagia	5	20
Abdominal mass	2	8
Abdominal pain	6	24
Discharge p/v	2	-
Concomitant second malignancy	1 (ovarian malignancy)	-

coexistent stage IA uterine carcinosarcoma and stage IIIB serous papillary adenocarcinoma of ovary. Forty percent (4/10) of patients who had taken only postoperative radiotherapy developed recurrence. Three of these four patients had high-grade tumors and all four of them had distant metastases. Among the group of 12 patients who had not taken any adjuvant treatment, five patients were lost after 1 to 6 months, two patients had significant residual disease, and five (100%) patients had recurrence. So, almost all patients who had not taken adjuvant treatment developed recurrence and in none of them lymphadenectomy was done on account of advanced stage.

Table 4 shows stage-wise analysis of recurrence in the two groups, who had taken and not taken adjuvant treatment. Three patients with advanced stages (stage III-2, unstaged-1) who had not taken adjuvant treatment developed recurrence within 1 to 3 months and two with stage I disease developed recurrence after period of 10 to 11 months. Among the adjuvant treatment taken group, one patient of stage IA had recurrence after 29 months, another of stage II after 16 months, and two patients with stage III after 7 and 22 months, respectively. One patient of stage IA had a very early recurrence, i.e., after 5 months, which can be attributed to coexistent ovarian carcinoma.

Sixty percent (15) of patients had undergone total abdominal

hysterectomy with bilateral salpingo-oophorectomy with bilateral pelvic lymph node dissection. Of the ten patients who did not undergo lymphadenectomy, two patients had significant residual disease and both of them expired within six months of surgery, three patients had taken adjuvant treatment and all of them had DFS of at least one year, rest of all five patients were of advanced stage and developed recurrence. Of these three patients who did not develop recurrence, two were of stage IA and third was in stage IIIA.

Table 5 presents the median and 3-year survival time according to postoperative treatment. The overall 3-year DFS of 13 patients who had taken adjuvant therapy was 40%. The differences in survival of patients with stage I and stage II-IV was statistically significant (P value=0.035).

The difference in survival of 13 patients who had taken adjuvant treatment was significantly more than the group who had not taken adjuvant therapy ($P=0.025$). However, these adjuvant treatment modalities had borderline statistical significance on overall survival of patients ($P=0.075$) [Figure 1].




Figure 1: Disease-free survival for 3 year was 40% for adjuvant treatment taken group

Table 3: Summary of postoperative treatment and recurrence

Treatment	No.	%	Recurrences
No adjuvant treatment taken	12	48	5 (2 had residual disease++, 5 were lost to follow up after 1-6 months)
Adjuvant treatment taken			
Only RT taken	13	52	5 (38%)
RT + CT taken	112		4 ^a 1 ^b (Associated stage IIIB ovarian carcinoma)

^aAll four patients who had taken only RT had distant metastases; ^bOne patient who had taken RT + CT had nonresectable pelvic recurrence. This patient had coexistent ca. ovary

Table 4: Stage-wise analysis of recurrence

Stage	Disease-free survival (months)	Recurrence	Site of recurrence	Recurrence rate	P value
Adjuvant treatment taken group (13) ^a				38.5	0.035
Only RT taken					
Stage I	29 (IA)	5/134/10	Lung/Peritoneum		
Stage II	16	1	Lung		
Stage III	7(IIIA), 22(IIIC1)	1	Lung/Peritoneum		
RT + CT taken					
Stage IV	(Coexistent ca. ovary)	21/21	Pelvic (Unresectable)		
No adjuvant treatment taken group (12) ^b				100	0.035
Stage I	11(IA), 10(IB)	5/52	Pelvic		
Stage III	1(IIIA), 3(IIIB)	2	Lung/Vault		
Unstaged	1	1	Pelvic/Liver		

^a2 patients lost within 6 months, 5 patients had recurrence; ^b5 patients lost after 1-6 months, 2 patients had residual disease, 5 patients had recurrence

Table 5: Median and 3-year disease-free survival according to stage and postoperative treatment

	No.	%	Median survival (95% CI) months	3-year DFS
Adjuvant treatment taken group	13 ^b	52	29 (12-45)	45%
Stage				
I	9	36		
II	3	12		
III	9	36		
IV	2	8		
Postoperative treatment				
Only RT	11	85		
RT + CT	2	15		
No adjuvant treatment taken group	12	48	7 (4-9)	None

^b12 patients who had not taken adjuvant treatment are excluded Log-Rank (Mantel-Cox) test confirmed the significant difference in median survival between adjuvant treatment taken and not taken group; DFS - Disease-free survival; CI - confidence interval

DISCUSSION

Our data indicated that the difference in survival of 13 patients who had taken adjuvant treatment was significantly more than the group who had not taken adjuvant therapy ($P=0.025$). The radiotherapy as treatment modality was associated with DFS period of three years in 40% of patients. Of the ten patients who had taken only radiotherapy as adjuvant treatment, four had recurrence after a median DFS period of 18.5 months. All these recurrences were distant metastases which prove the efficacy of radiotherapy to prevent locoregional recurrence, though not statistically. Many studies indicate that patients treated by adjuvant WPI alone have a significant reduction of recurrences within the radiation treatment field.^[9] Considering distant failures, which constituted the primary site of recurrence accounting for the compromised 5-year survival rates for both early and advanced disease, systemic therapy after initial surgical extirpation of uterus and adnexal structures would appear prudent.

There are no prospective studies indicating that adjuvant radiotherapy or chemoradiation confer a survival benefit in patients with uterine carcinosarcoma. However, because the risk of recurrence is high even in early stage disease, these treatment modalities are often used. Adjuvant radiotherapy has been frequently used in management of uterine sarcomas. Results with regard to improvement of survival are inconsistent. Some authors have found an improvement,^[10,11] while others reported no such effect on survival.^[12,13] Our data showed that adjuvant treatment

modalities had borderline statistical significance on overall survival of patients ($P=0.075$).

The limitations of our study are the small sample size in both postoperative treatment category and all inherent deficiencies of a retrospective study including the lacking of some data. Our series is too small for meaningful statistical analysis of correlation between adverse pathological findings, other than stage, treatment type, and survival.

Our results seem to indicate that in this highly aggressive malignancy, further exploration of potential outcome benefits of postoperative treatment, especially chemoradiation, is warranted in larger group of patients after comprehensive surgical staging.

REFERENCES

- Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology and end results analysis of 2677 cases of uterine sarcoma 1989-1999. *Gynecol Oncol* 2004;93:204-8.
- Berek JS, Hacker NF. Berek and Hacker's gynecol Oncol. 5th ed. Ahmedabad; 2010. p. 433-4.
- Sherman ME, Devessa SS. Analysis of racial differences in incidence, survival and mortality for malignant tumors of uterine corpus. *Cancer* 2003;98:176-86.
- Schweizer W, Demopoulous R, Beller U. Prognostic factors for MMMT of uterus. *Int J Gynecol Pathol* 1990;9:129-36.
- Ali S, Wells M. Mixed müllerian tumors of uterine corpus: A review. *Int J Gynecol Cancer* 1993;3:1-11.
- Spanos Jr WJ, Peters LJ, Oswald MJ. Patterns of recurrence in malignant mixed müllerian tumor of uterus. *Cancer* 1986;57:155-9.
- Callister M, Ramondetta LM, Jhingram A, Burke TW, Eifel PJ. MMMT of uterus: Analysis of patterns of failure, Prognostic factors and treatment outcomes. *Int J Radiat Oncol Biol Phys* 2004;58:786-96.
- Pecorelli S. Revised FIGO staging for carcinoma of vulva, cervix and endometrium. *Int J Gynecol Obstet* 2009;105:103-4.
- Chauveveinc L, Deniaud E, Plancher C, Sastre X, Amsani F, de la Rochefordiere A, *et al.* Uterine Sarcomas: The curie Institute experience. Prognosis factors and adjuvant treatment. *Gynecol Oncol* 1999;72:232-7.
- Le T. Adjuvant pelvic radiotherapy for uterine carcinosarcomain a high risk population. *Eur J Surg Oncol* 2001;27:282-5.
- Gerszten K, Faul C, Kounelis S, Huang Q, Kelley J, Jones MW. The impact of adjuvant radiotherapy on carcinosarcoma of uterus. *Gynecol Oncol* 1998;68:8-13.
- Chi DS, Mychalczak B, Saigo PE, Rescigno J, Brown CL. The role of whole pelvic irradiation in the treatment of early stage uterine carcinosarcoma. *Gynecol Oncol* 1997;65:493-8.
- Yamada SD, Burger RA, Brewster WR, Anton D, Kohler MF, Monk BJ. Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of uterus. *Cancer* 2000;88:2782-6.

How to cite this article: Dave KS, Chauhan A, Bhansali R, Arora R, Purohit S. Uterine carcinosarcomas: 8-year single center experience of 25 cases. *Indian J Med Paediatr Oncol* 2011;32:149-53.

Source of Support: Nil, **Conflict of Interest:** None declared.